Stock Taper
SCREENER COMPARE ANY 2 STOCKS
EYPT
EYEPOINT PHARMACEUTICALS, INC.
NASDAQ
$4.48
▼ DOWN 3.24% (-0.15)

KEY STATISTICS

Market Cap$375.61 M
52w High$19.11
52w Low$3.95
Dividend Yield—
Frequency—
P/E-1.20
Volume4.39M
Shares Out.83.84M

COMPANY

LEADERSHIP

Jay S. Duker
CHIEF EXECUTIVE
Jay S. Duker

COMPENSATION 2026

Salary$696,251
Stock Awards$1,610,700
Incentive Plan Pay$632,700
All Other Comp.$24,588
Total$5,568,352

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 27, 2005
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
214

PRICE TARGET

Target High$40.00
Target Low$5.00
Target Median$17.50
Target Consensus$20.67

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$232.15K
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2020-12-09Reverse1:10
2008-06-11Reverse1:4

PRICE

$4.48 ▼ DOWN 3.24% (−$0.15)
OVERLAYS
$4.40$4.50$4.609:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.48

About EyePoint Pharmaceuticals, Inc.

https://www.eyepoint.bio ↗

EyePoint Pharmaceuticals develops and commercializes ophthalmic treatments like ILUVIEN, YUTIQ, and DEXYCU for eye diseases, with ongoing development of innovative therapies and strategic collaborations worldwide.

INDUSTRY

Biotechnology

A PRODUCT EYEPOINT PHARMACEUTICALS, INC. IS KNOWN FOR

DURAVYU™ (vorolanib intravitreal insert)
DURAVYU™ (vorolanib intravitreal insert)

DURAVYU™ is an investigational, sustained-release intravitreal treatment for retinal diseases like wet AMD and DME, using bioerodible technology to deliver vorolanib and reduce injection frequency, currently in Phase 3 trials.

COMPETITORS

COMPETITOR
ABBV COMPARE
KOD COMPARE
NVS COMPARE
OCUL COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ4-2024Q1-2025Q2-2025Q3-2025
Y U T I Q Product$1.3M $600K ▼— —
Product$1.43M $715K ▼— $582K ▼
Royalty$687K $12.69M ▲— $234K ▼
License And Collaboration Agreement$21.15M $11.05M ▼$5.33M ▼$150K ▼

Revenue by Geography

MapREGIONFY2020FY2021FY2022FY2024
UNITED STATES$22.62M $35.99M ▲$40.48M ▲$42.05M ▲
CHINA$11.71M $851K ▼$823K ▼$1.12M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
117
LISTED HERE
18
RANKED BY POSITION SIZE
VTI
0.00% · 2.6M
IWM
0.01% · 2.0M
XPH
0.53% · 676.3K
SCHA
0.01% · 374.5K
DFAS
0.01% · 207.6K
FESM
0.01% · 141.2K
XRS2.F
0.01% · 70.8K
PRFZ
0.01% · 61.3K
SURI
0.20% · 38.6K
RSSL
0.01% · 36.7K
FSCC
0.05% · 27.1K
BBC
0.21% · 24.1K
PILL
0.36% · 19.1K
GSSC
0.01% · 14.7K
RTWO.L
0.01% · 4.1K
SGRW
0.05% · 3.3K
URTY
0.00% · 3.1K
USUE.DE
0.00% · 311

INSTITUTIONAL OWNERSHIP

SHARES OWNED
77.24%
HOLDERS
245
TOP 12 OF 245 · RANKED BY POSITION SIZE
Cormorant Asset Management, LP
8.3M sh · $118.55M
Suvretta Capital Management, LLC
8.3M sh · $106.94M
Blackrock, Inc.
7.5M sh · $106.72M
Federated Hermes, Inc.
6.0M sh · $109.94M
Adage Capital Partners Gp, L.L.C.
5.6M sh · $79.17M
Franklin Resources Inc
5.0M sh · $65.08M
Vanguard Group Inc
4.8M sh · $88.1M
Commodore Capital LP
4.6M sh · $65.78M
Blackrock Inc.
3.8M sh · $32.75M
Paradigm Biocapital Advisors LP
3.7M sh · $67.44M
Janus Henderson Group Plc
3.6M sh · $46.42M
Tcg Crossover Management, LLC
3.6M sh · $50.87M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Elston George
Purchase · 5.0K shares
2026-08-20
★
OFFICER: CHIEF FINANCIAL OFFICER
Elston George
Purchase · 65.0K shares
2026-08-20
★
DIRECTOR
Zaderej Karen L.
Purchase · 10.6K shares
2026-08-18
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Duker Jay S.
Sale · 8.1K shares
2026-07-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 3
BUY 3
SECTOR PERFORM 1
OVERWEIGHT 1
8 GRADES IN THE LAST 12 MONTHS
RBC Capital SECTOR PERFORM Chardan Capital NEUTRAL Citigroup BUY HC Wainwright & Co. NEUTRAL Jefferies BUY JP Morgan NEUTRAL Cantor Fitzgerald OVERWEIGHT Guggenheim BUY

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NRIX$26.21COMPARE
KOD$37.72COMPARE
SEPN$38.91COMPARE
BCAX$23.43COMPARE
KURA$12.66COMPARE
SVRA$5.26COMPARE
PRME$3.61COMPARE